4-苄氧基-1H-吲哚-2-羧酸甲酯 | 27748-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-苄氧基-1H-吲哚-2-羧酸甲酯
• 英文名称: 4-benzyloxyindole-2-carboxylic acid methyl ester
• 英文别名: 4-benzyloxy-indole-2-carboxylic acid methyl ester；Methyl 4-benzyloxy-2-indolecarboxylate；methyl 4-benzyloxyindole-2-carboxylate；4-Benzyloxyindol-2-carbonsaeuremethylester；methyl 4-(benzyloxy)-1H-indole-2-carboxylate；methyl 4-phenylmethoxy-1H-indole-2-carboxylate
• CAS: 27748-09-0
• 化学式: C₁₇H₁₅NO₃
• mdl: MFCD04972038
• 分子量: 281.311
• InChiKey: CDDYUJMTTJRWJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  4-苄氧基-1H-吲哚-2-羧酸甲酯 在 一水合肼 作用下， 反应 0.34h， 生成 4-benzyloxy-1H-indole-2-carboxylic acid furan-3-ylmethylene-hydrazide
  参考文献：
  名称：

  各种新型4-苄氧基-1 H-吲哚-2-羧酸（亚芳基）酰肼的合成，表征和光谱研究

  摘要：

  4-苯甲氧基吲哚-2-羧酸酰肼在回流条件下与酒精介质中的芳族和杂环醛反应，生成4-苄氧基-1 H-吲哚-2-羧酸（亚芳基）酰肼，这是一种重要的合成中间体。新型的药理活性化合物。我们在这里描述了通过常规以及微波辐射技术合成各种4-苄氧基-1 H-吲哚-2-羧酸（亚芳基）-酰肼的方法。这些化合物的结构已通过光谱技术（FTIR，NMR和MS）确认。还讨论了这些化合物的电子碰撞质谱碎片图的一些有趣特征。

  DOI：

  10.1002/jhet.5570420537
• 作为产物：
  描述：

  水杨醛 在 potassium carbonate 作用下， 以 xylene 为溶剂， 生成 4-苄氧基-1H-吲哚-2-羧酸甲酯
  参考文献：
  名称：

  Synthesis of A575C, a combined angiotensin converting enzyme inhibitor-beta adrenoceptor antagonist

  摘要：

  DOI：

  10.1016/s0040-4039(00)80213-0

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013102242A1

  公开（公告）日：2013-07-11

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及吡咯烷和氮杂环丙烷化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。
• Anti-inflammatory indole derivatives
  申请人：AstraZeneca AB

  公开号：US06569888B1

  公开（公告）日：2003-05-27

  Compounds of formula (I) or a pharmaceutically acceptable salt, in vivo hydrolysable ester, or an N—C1-6alkyl or N,N-di-(C1-6alkyl)amide thereof, where X is CH2 or SO2; R1 is an aryl optionally substituted by alkyl, alkenyl, alkynyl, halo, haloalkyl including perhaloalkyl such as trifluoromethyl, mercapto, alkoxy, haloalkoxy, alkenyloxy, alkynyloxy, hydroxyalkoxy, alkoxyalkoxy, alkanoyl, alkanoyloxy, cyano, nitro, amino, mono- or di-alkyl amino, oximino, sulphonamido, carbamoyl, mono or dialkylcarbamoyl or S(O)mR21 where m is defined above and R21 is hydrocarbyl; R4 is a group OR15 or S(O)qR15, where q is 0, 1 or 2 and R15 is a hydrogen-containing alkyl group substituted by at least one functional group as defined below, or an aryl group which is optionally substituted by one or more functional groups as defined below; and R2, R3, R5, R6 and R7 are specified organic groups. These compounds are useful in therapy, in particular of inflammatory disease, and methods of producing them as well as pharmaceutical compositions containing them are also described and claimed.

  化合物的结构式（I）或其药学上可接受的盐，在体内可水解的酯，或其N—C1-6烷基或N,N-二-(C1-6烷基)酰胺，其中X为CH2或SO2；R1为芳基，可选择地被烷基，烯基，炔基，卤素，卤代烷基（包括全氟烷基如三氟甲基），巯基，烷氧基，卤代烷氧基，烯氧基，炔氧基，羟基烷氧基，烷氧基烷氧基，烷酰基，烷酰氧基，氰基，硝基，氨基，单烷基或双烷基氨基，肟基，磺胺基，氨基甲酰基，单烷基或双烷基氨基甲酰基或S(O)mR21（其中m如上所定义，R21为烃基）取代的芳基；R4为OR15或S(O)qR15基团，其中q为0，1或2，R15为含氢烷基，取代至少一个如下所定义的功能基团的烷基，或者是可选择地被一个或多个如下所定义的功能基团取代的芳基；而R2、R3、R5、R6和R7为特定的有机基团。这些化合物在治疗中特别有用，尤其是在炎症性疾病中，同时还描述和声明了生产它们的方法以及含有它们的药物组合物。
• COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Elder Amy

  公开号：US20110144090A1

  公开（公告）日：2011-06-16

  Indole compounds are disclosed. Also disclosed are methods for using the compounds to treat human and animal disease, pharmaceutical compositions of the compounds, and kits including the compounds.

  揭示了吲哚化合物。还揭示了使用该化合物治疗人类和动物疾病的方法，该化合物的药物组成以及包括该化合物的试剂盒。
• Pharmaceutically active dipeptide derivatives
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0174162A2

  公开（公告）日：1986-03-12

  The invention relates to compounds of formula (I), physiologically acceptable salts thereof, formulations containing them, their preparation and their use in medicine. In formula (I) Q and Q'-Q8are independently selected hydrogen and C1-4 alkyl; A is a group of formula -(CO)k-(N09)m-(CH2)n - where k and m are either both 0 or both 1, n is from 1 to 6, Q9 is selected from hydrogen and C1-4 alkyl and any of the -(CH2)n groups independently are optionally substituted by one or two C1-4 alkyl groups; B is a C1-6 alkyl group; E and Z are independently selected from carboxy derivatives thereof; D is hydrogen or a C1-6 alkyl group which is optionally substituted by an amino group; (X) is a benzene ring or a naphthyl or indolyl ring system any of which is optionally substituted in any position by one or more substituents independently selected from C1-4 (itself optionally substituted by one or more halogen atoms (C1-4 alkoxy, halo, nitro, amino, carboxy, C1-4 alkoxycarbonyl and hydroxy; and -N Y is a pyrrolidinyl, oxazolidinyl or thiazolidinyl ring, or a ring system selected from indolinyl, quinolinyl and tetrahydroquinolinyl.

  本发明涉及式 (I) 化合物、其生理上可接受的盐、含有它们的制剂、它们的制备以及它们在医药中的应用。 的制剂及其在医药中的应用。 在式 (I) 中 Q和Q'-Q8分别独立地选为氢和C1-4烷基； A 是式-(CO)k-(N09)m-(CH2)n-的基团，其中 k 和 m 要么都是 0，要么都是 1，n 是 1 至 6，Q9 选自氢和 C1-4 烷基，且任何一个-(CH2)n 基团都独立地被一个或两个 C1-4 烷基任选取代； B 是 C1-6 烷基； E和Z各自选自其羧基衍生物； D 是氢或任选被氨基取代的 C1-6 烷基； (X) 是苯环或萘基或吲哚基环系，其中任一环系在任一位置任选被一个或多个取代基取代，这些取代基独立选自 C1-4（本身任选被一个或多个卤原子（C1-4 烷氧基、卤代、硝基、氨基、羧基、C1-4 烷氧基羰基和羟基）取代）；以及 -N Y 是吡咯烷基、噁唑烷基或噻唑烷基环，或选自吲哚啉基、喹啉基和四氢喹啉基的环系。
• New compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0234946A2

  公开（公告）日：1987-09-02

  The present invention is concerned with compounds of formula (I), physiologically acceptable salts thereof, formulations containing them, their preparation and their use in medicine. In formula (I) wherein: Q and Q1 - Q3 are hydrogen; A is a group of formula -CONH(CH2)n- , where n is 4 and Q9 is hydrogen; B is an isopropyl group; E is a carboxyl group; Z is a carboxyl or C2.6 carboalkoxy group; D is a methyl group; (X) is a naphthyl or indolyl ring system; and -N Y is a pyrrolidinyl ring; and physiologically acceptable salts thereof; with the condition that when (X) is a naphthyl ring system, the compound of formula (I) is: N-(1(S)-carboxy-5- [5-(2(R,S)-hydroxy -3-isopropyl- aminopropoxy) naphth-2- ylcarboxamidol pentyl)-(R,S)-alanyl-(S)- proline, or N-(1(S)- carboxy-5- [8-(2(R,S)- hydroxy-3-isopropyl- aminopropoxy) naphth -2-ylcarboxamido] pentyl)-(R,S)-alanyl-(S)- proline, or a half ester (wherein Z is C2-5 carboalkoxy) of either thereof, and when (X) is an indolyl ring system the compound of formula (I) is N-(1(S)-carboxy-5- [4-(2(S)- hydroxy-3-isopropyl- aminopropoxy) -1H-indol -2-yl-carboxamido] pentyl)-(S)-alanyl-(S)- proline, or a half ester (wherein Z is C2-5 carboalkoxy) thereof.

  本发明涉及式（I）化合物、其生理上可接受的盐、含有它们的制剂、它们的制备及其在医学中的应用。 在式 (I) 中 其中 Q 和 Q1 - Q3 是氢； A 是式 -CONH(CH2)n- 的基团，其中 n 是 4，Q9 是氢； B 是异丙基 E 是羧基 Z 是羧基或 C2.6 羧烷氧基 D 是甲基； (X) 是萘基或吲哚基环系；以及 -N Y 是吡咯烷基环；及其生理学上可接受的盐；条件是当(X)是萘基环系时，式(I)化合物是： N-(1(S)-羧基-5-[5-(2(R,S)-羟基-3-异丙基-氨基丙氧基)萘-2-甲脒戊基)-(R,S)-丙氨酰-(S)-脯氨酸，或 N-(1(S)-羧基-5-[8-(2(R,S)-羟基-3-异丙基-氨基丙氧基)萘烷-2-基甲酰氨基]戊基)-(R,S)-丙氨酰-(S)-脯氨酸，或其任一者的半酯(其中 Z 为 C2-5 羧基氧基)，当(X)为吲哚基环系时，式(I)化合物为 N-(1(S)-羧基-5-[4-(2(S)-羟基-3-异丙基-氨基丙氧基)-1H-吲哚-2-基-甲酰氨基]戊基)-(S)-丙氨酰-(S)-脯氨酸，或其半酯（其中 Z 为 C2-5 羧基烷氧基）。